You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePerflutren
Accession NumberDB00556  (APRD01177)
TypeSmall Molecule
GroupsApproved
DescriptionPerflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Structure
Thumb
Synonyms
1,1,1,2,2,3,3,3-Octafluoropropane
Definity
FC 218
Freon 218
Octafluoropropane
Octafluorpropan
Oktafluorpropan
Perfluoropropane
Perflutren
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DefinityInjection, suspension6.52 mg/mLIntravenousLantheus Medical Imaging, Inc.2001-07-31Not applicableUs
DefinitySuspension150 mclIntravenousLantheus Mi Canada Inc2002-02-16Not applicableCanada
LuminityInjection, solution150 μl/mlIntravenousLantheus Mi Uk Ltd.2006-09-20Not applicableEu
LuminityInjection, solution150 μl/mlIntravenousLantheus Mi Uk Ltd.2006-09-20Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICK0N3WH0SR
CAS number76-19-7
WeightAverage: 188.0193
Monoisotopic: 187.98722564
Chemical FormulaC3F8
InChI KeyQYSGYZVSCZSLHT-UHFFFAOYSA-N
InChI
InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11
IUPAC Name
octafluoropropane
SMILES
FC(F)(F)C(F)(F)C(F)(F)F
Pharmacology
IndicationUsed as an ultrasound contrast imaging in cardiology and radiology.
Structured Indications Not Available
PharmacodynamicsPerflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. It provide contrast enhancement of the endocardial borders during echocardiography. The perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood.
Mechanism of actionPerflutren is comprised of gas-filled microspheres that are injected or infused into the body. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

OFP is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids.

Route of eliminationNot Available
Half lifeThe mean half-life of OFP in blood 1.9 minutes
ClearanceNot Available
ToxicityThere is new temporal evidence that perflutren may be associated with new-onset seizure activity following perflutren microbubble contrast injection during dobutamine-atropine stress echocardiography. [PMID: 23432576]
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Perflutren.Approved
AmiodaronePerflutren may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Perflutren.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Perflutren.Approved
AnagrelidePerflutren may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
Arsenic trioxidePerflutren may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPerflutren may increase the QTc-prolonging activities of Artemether.Approved
AsenapinePerflutren may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Perflutren.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Perflutren.Approved
BedaquilinePerflutren may increase the QTc-prolonging activities of Bedaquiline.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
BuserelinBuserelin may increase the QTc-prolonging activities of Perflutren.Approved
CeritinibPerflutren may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquinePerflutren may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
CisapridePerflutren may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramPerflutren may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinPerflutren may increase the QTc-prolonging activities of Clarithromycin.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Perflutren.Approved
CrizotinibPerflutren may increase the QTc-prolonging activities of Crizotinib.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Perflutren.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Perflutren.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Perflutren.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Perflutren.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Perflutren.Approved
DisopyramidePerflutren may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilidePerflutren may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronPerflutren may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidonePerflutren may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Perflutren.Approved
DronedaronePerflutren may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
EliglustatPerflutren may increase the QTc-prolonging activities of Eliglustat.Approved
EribulinEribulin may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
EscitalopramPerflutren may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Perflutren.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Perflutren.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Perflutren.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
FlecainidePerflutren may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Perflutren.Approved
FluoxetinePerflutren may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolPerflutren may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Perflutren.Approved
Gadobenic acidPerflutren may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Perflutren.Approved
GemifloxacinPerflutren may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Perflutren.Approved
GranisetronPerflutren may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Perflutren.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Perflutren.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Perflutren.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
IbutilidePerflutren may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidonePerflutren may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Perflutren.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Perflutren.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Perflutren.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Perflutren.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Perflutren.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
LenvatinibPerflutren may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
LevofloxacinPerflutren may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Perflutren.Approved
LopinavirPerflutren may increase the QTc-prolonging activities of Lopinavir.Approved
LumefantrinePerflutren may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Perflutren.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Perflutren.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Perflutren.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Perflutren.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Perflutren.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Perflutren.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Perflutren.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Perflutren.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
NelfinavirNelfinavir may increase the QTc-prolonging activities of Perflutren.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Perflutren.Approved
NilotinibPerflutren may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Perflutren.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Perflutren.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
OfloxacinPerflutren may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Perflutren.Approved
OndansetronPerflutren may increase the QTc-prolonging activities of Ondansetron.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
PaliperidonePerflutren may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPerflutren may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Perflutren.Approved
PazopanibPerflutren may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidinePerflutren may increase the QTc-prolonging activities of Pentamidine.Approved
PimozidePerflutren may increase the QTc-prolonging activities of Pimozide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Perflutren.Approved, Investigational, Vet Approved
PrimaquinePerflutren may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamidePerflutren may increase the QTc-prolonging activities of Procainamide.Approved
PromazinePromazine may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Perflutren.Approved
PropafenonePerflutren may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Perflutren.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Perflutren.Approved
QuetiapinePerflutren may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidinePerflutren may increase the QTc-prolonging activities of Quinidine.Approved
QuininePerflutren may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Perflutren.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Perflutren.Approved
SaquinavirPerflutren may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Perflutren.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Perflutren.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
SotalolPerflutren may increase the QTc-prolonging activities of Sotalol.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Perflutren.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Perflutren.Approved
TelavancinPerflutren may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinPerflutren may increase the QTc-prolonging activities of Telithromycin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Perflutren.Approved
TetrabenazinePerflutren may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazinePerflutren may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Perflutren.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Perflutren.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
ToremifenePerflutren may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Perflutren.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Perflutren.Approved, Vet Approved
VandetanibPerflutren may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Perflutren.Approved
VemurafenibPerflutren may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Perflutren.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Perflutren.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Perflutren.Approved, Investigational
ZiprasidonePerflutren may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolPerflutren may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

James L. Webster, Steven H. Swearingen, Douglas W. Bruhnke, Leo E. Manzer, Elrey L. McCann, “Synthesis of perfluoropropane.” U.S. Patent US5220083, issued August, 1967.

US5220083
General References
  1. Quinones A, Benenstein R, Saric M: New-onset seizure after perflutren microbubble injection during dobutamine stress echocardiography. Echocardiography. 2013 Apr;30(4):E95-7. doi: 10.1111/echo.12149. Epub 2013 Feb 22. [PubMed:23432576 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (584 KB)
MSDSDownload (64 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9907
Caco-2 permeable+0.6518
P-glycoprotein substrateNon-substrate0.8894
P-glycoprotein inhibitor INon-inhibitor0.9583
P-glycoprotein inhibitor IINon-inhibitor0.9396
Renal organic cation transporterNon-inhibitor0.9256
CYP450 2C9 substrateNon-substrate0.865
CYP450 2D6 substrateSubstrate0.5549
CYP450 3A4 substrateNon-substrate0.7591
CYP450 1A2 substrateNon-inhibitor0.6831
CYP450 2C9 inhibitorNon-inhibitor0.8595
CYP450 2D6 inhibitorNon-inhibitor0.9581
CYP450 2C19 inhibitorNon-inhibitor0.8397
CYP450 3A4 inhibitorNon-inhibitor0.9509
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9136
Ames testNon AMES toxic0.9656
CarcinogenicityCarcinogens 0.6661
BiodegradationNot ready biodegradable0.944
Rat acute toxicity1.6879 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9796
hERG inhibition (predictor II)Non-inhibitor0.9174
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Lantheus medical imaging inc
Packagers
Dosage forms
FormRouteStrength
Injection, suspensionIntravenous6.52 mg/mL
SuspensionIntravenous150 mcl
Injection, solutionIntravenous150 μl/ml
Prices
Unit descriptionCostUnit
Optison vial56.16USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2107466 No2001-07-032012-03-18Canada
CA2256592 No2010-06-012017-06-16Canada
US6033645 No1996-06-192016-06-19Us
US6146657 No1992-12-222009-12-22Us
US8658205 No1999-04-202019-04-20Us
US8685441 No1999-01-132019-01-13Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point-147.6 °CPhysProp
boiling point-36.6 °CPhysProp
water solubility5.7 mg/L (at 15 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.146 mg/mLALOGPS
logP2.96ALOGPS
logP2.78ChemAxon
logS-3.1ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity17.54 m3·mol-1ChemAxon
Polarizability7.1 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.49 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
KingdomOrganic compounds
Super ClassOrganohalogen compounds
ClassOrganofluorides
Sub ClassNot Available
Direct ParentOrganofluorides
Alternative Parents
Substituents
  • Hydrocarbon derivative
  • Organofluoride
  • Alkyl halide
  • Alkyl fluoride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:38